Riskpilot← Back to searchSign inGet full accessBioExellence Oy
OYDissolvedY-tunnus 2678692-9Kalevankatu 3-A41Research and experimental development on natural sciences and engineering · NACE 7210Est. 2015— employees
Revenue 2024
EUR 15K
-7% vs 2022
EBITDA margin
-16.1%
-339% vs 2022
Equity ratio
-48.5%
Financial strength
Net profit 2024
EUR -2K
-399% vs 2022
| Revenue | EUR 15K | -7% |
| EBITDA | EUR -2K | -339% |
| Net profit | EUR -2K | -399% |
| Total assets | EUR 5K | — |
| Equity | EUR -2K | — |
| Employees | — | — |
Legal name
BioExellence Oy
Y-tunnus number
2678692-9
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26. helmikuuta 2015
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on harjoittaa teollisuus- ja palvelutoimintaa huomioiden kestävän kehityksen vaatimukset, kuten m.m. harjoittaa bioenergiatoimintaa, poistaa ympäristöhaittoja, suorittaa maanparannusta tai muuten valmistaa, myydä tai vuokrata alan tavaroita, sekä harjoittaa alaan liittyvää palvelutoimintaa. Yhtiö voi harjoittaa myös muuta laillista liiketoimintaa. Yhtiö voi omistaa ja hallita kiinteää omaisuutta ja osakehuoneistoja sekä vuokrata ja käydä kauppa niillä sekä käydä arvopaperikauppaa.
Address
Kalevankatu 3-A41
Phone
+3580503821632
Email
toivo.tt@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2022 | 2024 |
|---|---|---|---|---|
| Revenue | — | — | 16 | 15 |
| Staff expenses | — | — | −3 | −15 |
| EBITDA | 0 | 0 | 1 | −2 |
| Depreciation & amort. | −0 | −0 | — | −0 |
| EBIT | 0 | 0 | 1 | −2 |
| Net financials | — | — | — | 0 |
| Profit before tax | 0 | 0 | 1 | −2 |
| Tax | −0 | −0 | 0 | −0 |
| Net profit | 0 | 0 | 1 | −2 |
| Item | 2019 | 2020 | 2022 | 2024 |
|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 5 |
| Equity | 0 | 0 | 0 | −2 |
| Long-term debt | — | — | — | 0 |
| Short-term debt | — | — | 0 | 7 |
| Total debt | — | — | 0 | 7 |
EBITDA margin
-16.1%
This company
15.8%
Market median
-202% vs market
20192024
Equity ratio
-48.5%
This company
38.2%
Market median
-227% vs market
20192024
Return on equity
-238500.0%
This company
18.4%
Market median
-1296296% vs market
20192024
Net profit margin
-16.1%
This company
8.1%
Market median
-299% vs market
20192024
Asset turnover
3.02×
This company
1.12×
Market median
+170% vs market
20192024
Debt / equity
3.06×
This company
0.62×
Market median
-394% vs market
20192024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
MS Deputy Member | Deputy Member | 2018 – 2022 |
TO Chief Executive Officer | Chief Executive Officer | 2015 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2018 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioExellence Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikko Samuli Siitonen | Deputy Member | 0 companies |
| Timo Olavi Saini | Chief Executive Officer | 0 companies |
| Toivo Lepmets | Board of Directors | 0 companies |